From Mushrooms to Molly, the 'Wild West' of Medical Psychedelic Regulation

Globally, access to psychedelic use for mental health treatment has exploded. In the U.S., more than 900 clinics administer ketamine for treatment-resistant depression, after the FDA approved “esketamine,” a ketamine-derivative, in 2019.

Oregon became the first state to regulate the use of psilocybin, which is found in mushroom species and has hallucinogenic effects. Colorado followed in 2024. Some states require physicians to be on site and to record adverse events. Others do not. Some require extensive training, others a weekend course.

This reporting project looks into how those seeking help can know what to expect and what to ask. And what does the future bring in terms of psychedelic research and treatment?